As­traZeneca's mon­o­clon­al an­ti­body miss­es pri­ma­ry end­point in mid-stage tri­al in COPD

As­traZeneca’s an­ti-IL-33 mon­o­clon­al an­ti­body failed a Phase 2a study in chron­ic ob­struc­tive pul­monary dis­ease, though the com­pa­ny not­ed there were still “en­cour­ag­ing clin­i­cal ef­fi­ca­cy sig­nals …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER